EICHORCondition: Advanced Cancer · Sponsor: Joanne Wolfe, MD, MPH
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
PediQUEST Response proposes a new system of care that expects to improve quality of life in children, adolescents, and young adults with advanced cancer and their parents. The investigators want to learn whether patients that are cared for using PediQUEST Response do in fact feel better than those receiving usual care. National recommendations call for early palliative care (PC) integration for seriously ill children to ease suffering, however, very few randomized controlled trials (RCTs) have evaluated whether PC improves child and family outcomes. In prior work, the investigators developed the Pediatric Quality of Life and Evaluation of Symptoms Technology (PediQUEST/PQ), a software that collects electronic Patient-Reported Outcomes (e-PROMS) and generates feedback reports. Now, the PI and research team developed PediQUEST Response (Response to Pediatric Oncology Symptom Experience). PediQUEST Response includes an enhanced PediQUEST system (web-based and with an App that allows to answer surveys and see reports), that is coupled with early integration of a palliative care consulting team (Response team). This dual strategy will help to standardize the family report of distress, which will be done through the PediQUEST system. It will also help standardize the providers' response to such distress, as providers will be specifically trained. Pilot work for PediQUEST Response found it feasible, well received by families and oncologists, and potentially effective. Thus, the o…
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion criteria: Pediatric oncology patients (children, adolescents, or young adults), and one of their parents, receiving routine cancer care at one of the participating centers -and not in remission and off cancer-directed treatment-that have: * (i) advanced cancer defined as: at least a 2-week history of progressive, recurrent, or non-responsive cancer of any type, or any brainstem tumor, or a grade IV Glioblastoma Multiforme, or decision not to pursue cancer-directed therapy in place, or or any other progressive/recurrent solid or brain tumor, and are * (ii) palliative care naive, defined as the palliative care team not currently integrated into their regular cancer care. Exclusion criteria: The patient-parent dyad would be excluded if * patients are older than 18 years of age and no parent is involved in his/her care, or * if patient is under the care of foster parents who do not have legal guardianship, or * if both parents do not speak English or Spanish, or are unable to understand and complete surveys, or * if the patient has a non-brainstem low-grade glioma with localized progression/relapse only, or * is expected to receive a stem cell transplant within the next 18 weeks, or * life expectancy is less than two months.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | — |
| Boston Children's Hospital | Boston, Massachusetts, United States | — |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | — |
| The Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | — |
| Texas Children's Hospital | Houston, Texas, United States | — |
| Seattle Children's Research Institute | Seattle, Washington, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03408314